B
ile acids (BAs) are amphipathic detergent molecules synthesized by the liver and they facilitate the small intestinal absorption of lipids and fat-soluble vitamins. 1 Their overall structure resembles a cholesterol molecule, but the changes made by colonic bacteria change the BA effects on colonic permeability and secretion. Lithocholic acid (LCA) and deoxycholic acid (DCA) are the major BAs present in the colon and stool. Chenodeoxycholic acid (CDCA) and DCA are the known secretory BAs. 2 An increase in the fecal excretion and a change in the proportion of the various BAs in stool characterize bile acid malabsorption (BAM), resulting in diarrhea or irritable bowel syndrome with diarrhea (IBS-D), 3, 4 which are associated with increased colonic water and mucus secretion, colonic motility, and membrane permeability. 5, 6 BAM has been reported in 10% to 33% of patients with IBS-D or functional diarrhea. 7 The diagnosis of BAM is based on measurement of 75 selenium homotaurocholic acid test retention, where available, or on 48-hour fecal BA excretion and fasting serum biomarkers: 7a-hydroxy-4-cholesten-3-one (C4), a direct marker of hepatic BA synthesis; and fibroblast growth factor (FGF19), an endocrine hormone released by enterocytes providing negative feedback for BA synthesis. 8, 9 Multiple studies have confirmed the presence of increased fecal BAs, C4, colonic transit, and decreased FGF19 in patients with BAM as compared with healthy volunteers and constipation controls. 10, 11 In addition, there are increased proportions of individual secretory BAs, DCA, and CDCA in 48-hour fecal BA measurements 12, 13 in patients with IBS-D. Less is known about the potential role of BAs in patients with constipation. In a preliminary study, Shin et al 12 established that although there was no significant decrease in total fecal BAs in patients with IBS with constipation (IBS-C) as compared with healthy volunteers, patients with IBS-C had decreased proportions of DCA and CDCA and an increased proportion of the nonsecretory LCA as compared with healthy volunteers. Fasting serum C4 was not significantly different in IBS-C and healthy volunteers, and serum C4 and FGF19 measurements did not augment the utility of measurement of total fecal BAs for discriminating among IBS-C, IBS-D, and healthy volunteers. 8 An interesting report described a paradoxic increase in serum C4 in patients with slowtransit constipation compared with functional constipation, suggesting a compensatory increase in BA synthesis to provide an endogenous laxative agent. 14 This intriguing observation has not been corroborated or replicated.
The aims of this study were to compare fecal BAs and serum BAM biomarkers (C4 and FGF19) in IBS-C and healthy volunteers, and to assess the relationship of these biomarkers and colonic transit in patients with IBS-C.
Methods

Participants and Study Design
This was a single-center, retrospective study. There were 45 patients with IBS-C, defined by Rome III criteria, and 184 healthy volunteers who had participated in research studies within the past 10 years. Eligibility criteria, methods of selection, periods of recruitment, and data collection were included in prior publications. 8, 11, 12 Patients with IBS-C resided in local communities in southeastern Minnesota to avoid tertiary referral bias.
We collected previously measured fasting serum FGF19 and C4 levels, and 48-hour total and individual (CDCA, cholic acid, DCA, and LCA) fecal BA data from patients with IBS-C and healthy volunteers. From the IBS-C cohort, we also obtained 24-and 48-hour colonic transit data. Figure 1 shows the distribution of patients with available quantitative data between the 2 cohorts.
Measurement of Quantitative Data
Fasting serum 7a-hydroxy-4-cholesten-3-one and fibroblast growth factor 19. The C4 assay performed in our center (adapted from Galman et al 15 ) is based on high-performance liquid chromatography/tandem mass spectrometry. Forty-eight-hour total and individual fecal bile acids.
Patients were instructed to consume a 100 g fat diet for 2 days before stool collection was started and for 2 days during stool collection. The details of extraction, measurement by liquid chromatography tandem-mass spectrometry, analysis, and performance characteristics have been described in detail previously. 12 The 48-hour total fecal BAs (mmol/48 h) and the absolute values (mmol/48 h) and proportions of individual BAs (%) were measured. Twenty-four-and forty-eight-hour colonic transit. The scintigraphic colonic transit test and its performance characteristics have been described in detail. 18 Briefly, after an overnight fast, patients ingest indium-111 adsorbed on activated charcoal in a methacrylatecoated, delayed-release capsule that has been shown to dissolve in the ileocolonic region. Patients then were fed 3 meals of known caloric value and standard proportions of carbohydrates, protein, and fat. Abdominal scintiscans were obtained every hour for the first 6 hours and at 8, 24, and 48 hours after ingestion of the indium-111 capsule. The validated colonic transit measurements were geometric center at 24 and 48 hours.
Statistical Analysis
Because our sample sizes for both healthy volunteers and patients with IBS-C were relatively small, we elected to use the 10th and 90th percentiles for our parameter cut-off values. Altman and Bland 19 showed that the 10th and 90th percentiles would be more appropriate for skewed samples than the traditional 5th and 95th percentile cut-off values. We calculated the 10th percentile of C4 values (ng/mL) in the 184 healthy volunteers and fecal BAs (mmol/48 h) in 46 healthy volunteers to represent the lower normal limit. We appraised the 90th percentile of FGF19 in 50 healthy volunteers because it is known that low serum FGF19 is associated with diarrhea resulting from BAM.
We estimated the number of patients with IBS-C with results below the 10th percentile of healthy volunteers for total fecal BAs (in 39 IBS-C patients) and serum C4 (in 45 IBS-C patients), and above the 90th percentile of healthy volunteers based on FGF19 (in 43 IBS-C patients).
For analysis of the individual BAs, we compared the proportions and absolute values of IBS-C and healthy volunteers using the Wilcoxon rank-sum test.
To understand the relationships among C4, FGF19, fecal BAs, and colonic transit, we performed Spearman correlations and graphed the data with best-fitting regression lines using the regression wizard on SigmaPlot (Systat Software, San Jose, CA). The graphs are variations of rectangular hyperbola and hyperbolic decay, depending on which model best fit the data on scatter plots. The specific type of graph and the associated equations are described in the Figures 2-4 . Bonferroni correction for multiple correlation tests was not used because this was a hypothesis-generating, post hoc analysis, and the results of the individual tests are more important than the collective analysis. 20 
Results
Demographics
In the healthy volunteers, there was a 1.5 ratio of female to male participants (110:74) and comparable average age (42.3 AE 13 y) with those in the IBS-C cohort. Patients with IBS-C were all female participants, overweight (average body mass index AE SD, 26.2 AE 4.2 kg/m 2 ), and aged 43.8 AE 9.5 years.
Serum Biomarkers and Total and Individual Fecal Bile Acids in Healthy Volunteers
Because the patient cohort (IBS-C) consisted of only female volunteers, we calculated the healthy volunteer-based cut-off values for the combined group of both males and females, and exclusively for the female cohort.
Male and female healthy volunteer parameter cut-off values. The 10th percentile of serum C4 (n ¼ 184) was 5.05 ng/mL and the 48-hour fecal BAs (n ¼ 46) was 109.5 mmol/48 h. The 90th percentile of serum FGF19 (n ¼ 50) was 267.0 pg/mL. Table 1 shows the proportions and absolute values of the individual fecal BAs (n ¼ 25) in healthy volunteers. (9.3%), and the C4 was decreased in 2 of 45 (4.4%). However, there was not complete concordance between abnormal serum biomarkers and decreased 48-hour total fecal BAs. Table 1 shows the proportions and values for the individual fecal BAs. There was a significantly higher percentage of LCA (P ¼ .034) and a lower percentage of DCA (P ¼ .027) in patients with IBS-C.
Exclusively female healthy volunteer parameter cut-off value. Even with the cut-off values for 48-hour total fecal BAs and fasting serum C4, the number of patients with IBS-C with bile acid deficiency did not change: 6 of 39 (15.4%) and 2 of 45 (4.4%), respectively. For fasting serum FGF19, there was 1 less patient who showed BA deficiency (3 of 43; 7.0%). Table 2 shows the Spearman correlations, and Figures 2, 3, and 4 show the scatter plots with best-fit regression lines of the data collected from patients with IBS-C. Figure 2 shows a significant reciprocal relationship between fasting serum FGF19 and C4. Figure 3 shows direct correlations between serum C4 or the 48-hour fecal BAs and 48-hour colonic transit. Figure 4 shows the inverse correlation of FGF19 and colonic transit.
Relationships Between Serum and Fecal Biomarkers and Colonic Transit in Patients With Irritable Bowel Syndrome With Constipation
Discussion
Our study showed that there is a subgroup of approximately 15% of patients with IBS-C who have decreased 48-hour fecal BAs. Of the fasting serum biomarkers, 4.3% of patients with IBS-C had low serum C4 and 9.3% had increased serum FGF19. When adjusting the control group to include only female participants to match the IBS-C patient cohort of exclusively females, the prevalence of BA deficiency did not alter significantly. There was a significant direct correlation between fecal BA excretion and serum C4 and colonic transit, and there was an inverse correlation between serum FGF19 and colonic transit. As shown in Figure 2 , serum FGF19 and C4 showed a significant inverse relationship. This has been shown in multiple prior studies evaluating BA diarrhea in patients with IBS-D. These observations show that a portion of patients with IBS-C may suffer from colonic BA deficiency as the underlying pathophysiology. Importantly, when such patients with IBS-C are refractory to standard treatment of constipation, they may be candidates for treatment with strategies that increase intracolonic BA concentrations such as BA supplementation or inhibitors of the ileal BA transporter, as discussed later.
The observations in this study have practical and clinical implications for future studies as well as insights relative to prior clinical trials. For example, Rao et al 21 provided supplemental chenodeoxycholate to patients with IBS-C and functional constipation and showed improvements in colonic transit time, frequency, and consistency of stool. In addition, when elobixibat, an inhibitor of the ileal bile acid transporter that is responsible for approximately 95% of BA reabsorption in the terminal ileum, was administered to patients with functional constipation, it also improved colonic transit, stool consistency, and frequency. 22 Elobixibat resulted in increased fasting serum C4 and decreased FGF19, secondary to increased BA synthesis after increased fecal BA loss. 23, 24 Thus, there are potential therapeutic approaches to correct the abnormal biochemical parameters, given that the patients' fasting serum C4 was increased to greater than 10 ng/mL with elobixibat, 23 which could correct the low C4 ( 5.05 ng/mL) in a subgroup of patients with IBS-C in our current study.
Previous studies have shown decreased fecal BAs in a subset of patients with IBS-C compared with patients with IBS-D, but were unable to show statistical significance when compared with healthy volunteers. 11, 12 When evaluating the percentage of major individual primary and secondary BAs, our data showed a significant increase in LCA (P ¼ .034) and a decrease in the proportion of the secretory BA, DCA (P ¼ .027), in patients with IBS-C compared with healthy volunteers. This difference in individual BA proportions has been replicated in other studies. 12 In constipated children, there was no difference in the proportion of DCA, but there was increased sulfonated CDCA. The sulfonation removes the active secretory component of the BA. 25 There are 2 plausible hypotheses regarding constipation and fecal BA measurements. First, a decreased proportion of secretory fecal BAs results in constipation. At face value, our data would support this hypothesis in up to 15% of patients with IBS-C because they had low total fecal BA and DCA excretion. A second hypothesis is that increased colonic transit time in constipation results in increased passive absorption of fecal BAs and, hence, lower excretion of secretory BAs such as DCA. The precise contribution of colonic transit to the fecal excretion of individual BAs has been the subject of few previous reports. Within the colon, there is passive absorption of unconjugated, dihydroxy BAs, which include DCA (3,12 di-a hydroxylated) and UDCA (3a, 7b di-hydroxylated). 26 When constipated patients were given senna to accelerate colonic transit, it was observed that the biliary DCA (which must have been reabsorbed through the colonic mucosa) was decreased. 26 Conversely, healthy volunteers who received loperamide to decelerate colonic transit had increased biliary DCA. 27 Similarly, in patients with acromegaly, octreotide slowed colonic transit, yielding an increase in serum DCA. 28 
Conclusions
The current data are consistent with the hypothesis that a subset of patients with IBS-C has decreased total fecal BAs and a percentage of fecal secretory BAs, which is correlated significantly to a decrease in colonic transit. The serum biomarkers C4 and FGF19 were not always concordant with total fecal BAs. Based on our data, we believe that 48-hour total and the percentage of fecal secretory BAs will be considered the gold standard until further studies are completed. Given the potential limitations of a retrospective analysis, future studies are planned to confirm these findings in a prospective cohort of patients with functional constipation and IBS-C.
